Unique ID issued by UMIN | UMIN000034543 |
---|---|
Receipt number | R000039380 |
Scientific Title | Phase I Dose-Escalation Study of Accelerated Hyperfractionation and Intensity-modulated Radiation Therapy in Patients with Locally Advanced Non Small Cell Lung Cancer |
Date of disclosure of the study information | 2018/11/01 |
Last modified on | 2023/10/21 10:29:20 |
Phase I Dose-Escalation Study of Accelerated Hyperfractionation and Intensity-modulated Radiation Therapy in Patients with Locally Advanced Non Small Cell Lung Cancer
Phase I Dose-Escalation Study of AHF and IMRT in Patients with Locally Advanced NSCLC
Phase I Dose-Escalation Study of Accelerated Hyperfractionation and Intensity-modulated Radiation Therapy in Patients with Locally Advanced Non Small Cell Lung Cancer
Phase I Dose-Escalation Study of AHF and IMRT in Patients with Locally Advanced NSCLC
Japan |
Non-small cell lung carcinoma (NSCLC)
Pneumology | Hematology and clinical oncology | Radiology |
Malignancy
NO
To estimate the maximum tolerated dose and to determine the recommended dose of accelerated hyperfractionation and intensity-modulated radiation therapy for locally advanced NSCLC
Safety
incidence of Grade 3 or more acute adverse events within 90 days after chemoradiotherapy
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Chemoradiotherapy consists of CBDCA (AUC2, day 1, 8, 15, 22), PTX (40 mg/m2, day 1, 8, 15, 22) and AHF and IMRT (56-72 Gy/40 fr:56 Gy/40 fr at level 0, 60 Gy at level 1, 64 Gy at level 2, 68 Gy at level 3 and 72 Gy at level 4)
20 | years-old | <= |
90 | years-old | > |
Male and Female
1) Histologically proven NSCLC
2) Clinical stage IIIA or IIIB Locally Advanced NSCLC
3) Aged 20 to 90 years old, ECOG Performance status 0 or 1
4) Without previous chemotherapy for primary illness
5) Without previous radiotherpy for chest
6) Adequate organ functions
7) Written informed consent
1) Simultaneous or metachronous (within 5 years) double cancers , with the exception of intramucosal tumor curable with local therapy
2) Active infection requiring systemic therapy
3) With severe complications
4) History of serious drug allegies
5) Patients with unstable and uncontrollable diabetic mellitus, hypertension, kidney disease, liver disease.
6) Patients with intersitial pneumonia or pulmonary fibrosis detectable on chest radiography
7) Women during pregnancy or breast-feeding, or patients who wish pregnancy
8) Patients that physicians consider inappropriate for this study
15
1st name | Noriko |
Middle name | |
Last name | Kishi |
Graduate School of Medicine, Kyoto University
Department of Radiation Oncology and Image-applied Therapy
606-8507
54 Shogoin Kawaharacho Sakyo-ku, Kyoto
0757513762
kishin@kuhp.kyoto-u.ac.jp
1st name | Noriko |
Middle name | |
Last name | Kishi |
Graduate School of Medicine, Kyoto University
Department of Radiation Oncology and Image-applied Therapy
606-8507
54 Shogoin Kawaharacho Sakyo-ku, Kyoto
075-751-3762
kishin@kuhp.kyoto-u.ac.jp
Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University
None
Other
Graduate School of Medicine, Kyoto University, Ethics Committe
54 Shogoin Kawaharacho Sakyo-ku, Kyoto
075-753-4680
ethcom@kuhp.kyoto-u.ac.jp
NO
京都大学医学部附属病院(京都府)
2018 | Year | 11 | Month | 01 | Day |
Unpublished
Enrolling by invitation
2018 | Year | 09 | Month | 01 | Day |
2018 | Year | 05 | Month | 09 | Day |
2018 | Year | 09 | Month | 01 | Day |
2025 | Year | 05 | Month | 09 | Day |
2018 | Year | 10 | Month | 17 | Day |
2023 | Year | 10 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039380